Common Stock
- Symbol
- RVP
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
RVPNYSE_AMERICANEQUITYCurrent
Item 8.01 Other Events. On March 27, 2026, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99.1, announcing results for 2025. On March 27, 2026, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99.2, announcing the declaration of a dividend to the Series II and Series III Class B Convertible Preferred Stock shareholders.
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.
Retractable Technologies, Inc. · 8-K · Filed 2026-03-27
EX-99.1 2 tm269857d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 RETRACTABLE TECHNOLOGIES, INC. REPORTS RESULTS FOR 2025 LITTLE ELM, Texas, March 27, 2026 - Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 27, 2026 with the U.S. Securities and Exchange Commission. The Company’s revenues for 2025 increased 15.8%. The Company’s revenues were approximately $38.3 million in 2025 as compared to approximately $33.0 million in the prior year. Domestic revenues increased 9.7% principally due to an increase in VanishPoint® and EasyPoint® needle sales. International revenues increased 64.0% predominantly due to higher EasyPoint® needle sales. Comparability of 2025 to 2020-2023 financial results is challenging due to the unusual volume of pandemic sales in those years. The Company’s operating costs remain high since its facility expansion and, more recently, an increase in domestic production in connection with 2024-2026 tariffs. Total operating expenses were $21.2 million in 20…
Open exhibit ↗EX-99.2 3 tm269857d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 RETRACTABLE TECHNOLOGIES, INC. DECLARES DIVIDENDS TO SERIES II AND III CLASS B PREFERRED STOCK SHAREHOLDERS LITTLE ELM, Texas, March 27, 2026 - Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning January 1, 2026 through March 31, 2026. The dividends will be paid on April 20, 2026 to shareholders of record as of the close of business on April 10, 2026. Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections result…
Open exhibit ↗